Innoviva, Inc. (INVA)
NASDAQ: INVA · Real-Time Price · USD
20.61
+0.52 (2.59%)
Aug 13, 2025, 4:00 PM - Market closed
Innoviva Revenue
Innoviva had revenue of $100.28M in the quarter ending June 30, 2025, with 0.39% growth. This brings the company's revenue in the last twelve months to $370.23M, up 12.02% year-over-year. In the year 2024, Innoviva had annual revenue of $358.71M with 15.54% growth.
Revenue (ttm)
$370.23M
Revenue Growth
+12.02%
P/S Ratio
3.49
Revenue / Employee
$2,915,189
Employees
127
Market Cap
1.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 358.71M | 48.25M | 15.54% |
| Dec 31, 2023 | 310.46M | -20.88M | -6.30% |
| Dec 31, 2022 | 331.34M | -60.53M | -15.45% |
| Dec 31, 2021 | 391.87M | 55.07M | 16.35% |
| Dec 31, 2020 | 336.79M | 75.78M | 29.03% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
INVA News
- 1 day ago - Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award - Business Wire
- 7 days ago - Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress - Business Wire
- 2 months ago - FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 - Business Wire
- 2 months ago - Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults - Business Wire
- 2 months ago - Innoviva to Participate in Upcoming Investor Conferences - Business Wire
- 3 months ago - ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections - Business Wire
- 3 months ago - Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States - GlobeNewsWire
- 3 months ago - Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress - Business Wire